Thor Agustsson, DO
Psychiatry · Nashua, NHNPI 1427219948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 43.7% of the total. Reporting peaked in 2019 at $1,729 and has fallen 94.7% since, to $92 in 2022. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $12.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neos Therapeutics, LP$467
- Takeda Pharmaceuticals U.S.A., Inc.$328
- Sunovion Pharmaceuticals Inc.$309
- Johnson & Johnson$225
- Lundbeck LLC$110
- plus $416 from 11 others
What the payments were for
- Food & beverage$3,288100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $1,440 |
| Neos Therapeutics, LP | 36 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $328 |
| Sunovion Pharmaceuticals Inc. | 19 | $309 |
| Johnson & Johnson | 20 | $225 |
| Lundbeck LLC | 7 | $110 |
| Supernus Pharmaceuticals, Inc. | 5 | $94 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Shire North American Group Inc | 4 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Merck | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $14 |
| Rhodes Pharmaceuticals L.p. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$3,295 in reported general payments places this provider in the 90th percentile of 166 psychiatry providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $3,008 |
| Bupropion XlBupropion Hcl | 40 | $988 |
| Clonazepam | 23 | $506 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $496 |
| Lamotrigine | 19 | $386 |
| Lorazepam | 28 | $268 |
| Fluoxetine Hcl | 15 | $199 |
| Aripiprazole | 11 | $88 |
| Escitalopram Oxalate | 12 | $75 |
| Alprazolam | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Nashua
- Stephen EllenNashua$1.4M
- Darwyn ChernNashua$2K
- Susana LugoNashua$790
- Marilou Patalinjug TynerNashua$650
- Santharam YadatiNashua$614
- Kenneth GoldenNashua$398
- John MillerExeter$2.7M
- Michael McNamaraManchester$754K
- Kenneth BrownBrentwood$94K
- Janet CarellaManchester$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.